Antibacterial and anti-biofilm activity of plumbagin against multi-drug resistant clinical bacterial isolates

Mohammad A. Alfhili; Irfan Ahmad; Yasser Alraey; Abdulaziz Alangari; Taha Alqahtani; Ayed A. Dera

doi:10.15537/smj.2022.43.11.20220446

Abstract

Objectives: To evaluate the antibacterial activity of plumbagin (PGN) against multidrug resistance (MDR) clinical isolates.

Methods: This study was carried out at the Department of Clinical Lab Sciences, King Khalid University from October 6, 2021 to December 14, 2021. We investigated the antibacterial and anti-virulence activity of PGN against MDR Gram-negative (Escherichia coli, Klebsiella pneumoniae, Salmonella Typhi, and Pseudomonas aeruginosa) and Gram-positive (Staphylococcus aureus [S. aureus], Staphylococcus saprophyticus [S. saprophyticus], Streptococcus pyogenes, and Enterococcus faecalis) clinical bacterial isolates. Agar well diffusion, microdilution assay, colony count method, biofilm formation, and time-kill kinetics were employed to probe the MIC, MBC, and anti-virulence activity of PGN.

Results: Plumbagin inhibited the growth of all tested isolates, with S. saprophyticus exhibiting the highest sensitivity. MIC values ranged from 0.029 to 0.117 µg/mL whereas MBC ranged from 0.235 to 0.94 µg/mL, with 79% to 99% growth inhibition. Moreover, all tested isolates showed a marked decrease in biofilm formation, with S. saprophyticus and S. aureus being the most sensitive.

Conclusion: Plumbagin is a stand-alone, broad spectrum antibacterial with promising potential against the rising threat of antimicrobial resistance.

Keywords:

Footnotes

Disclosure. This study was funded by the Deanship of Scientific Research through the Vice Deanship of Scientific Research Chairs; Research Chair of Medical and Molecular Genetics, King Saud University, Riyadh, Kingdom of Saudi Arabia.

Received August 11, 2022.
Accepted October 20, 2022.

This is an Open Access journal and articles published are distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC). Readers may copy, distribute, and display the work for non-commercial purposes with the proper citation of the original work.

View Full Text